Ocular Therapeutix, Inc.
OCUL
$11.04
$0.282.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.95M | 55.78M | 56.66M | 59.65M | 63.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.95M | 55.78M | 56.66M | 59.65M | 63.72M |
| Cost of Revenue | 203.67M | 193.50M | 177.98M | 155.32M | 133.26M |
| Gross Profit | -151.72M | -137.71M | -121.31M | -95.67M | -69.54M |
| SG&A Expenses | 118.30M | 113.72M | 107.42M | 100.31M | 94.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 321.97M | 307.22M | 285.40M | 255.63M | 227.40M |
| Operating Income | -270.02M | -251.43M | -228.73M | -195.98M | -163.68M |
| Income Before Tax | -265.94M | -249.67M | -216.75M | -192.71M | -193.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -265.94 | -249.67 | -216.75 | -192.71 | -193.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -265.94M | -249.67M | -216.75M | -192.71M | -193.51M |
| EBIT | -270.02M | -251.43M | -228.73M | -195.98M | -163.68M |
| EBITDA | -265.69M | -247.41M | -224.82M | -192.13M | -159.90M |
| EPS Basic | -1.44 | -1.44 | -1.28 | -1.15 | -1.26 |
| Normalized Basic EPS | -0.90 | -0.90 | -0.80 | -0.69 | -0.63 |
| EPS Diluted | -1.44 | -1.44 | -1.28 | -1.15 | -1.26 |
| Normalized Diluted EPS | -0.90 | -0.90 | -0.80 | -0.69 | -0.63 |
| Average Basic Shares Outstanding | 748.83M | 693.93M | 677.00M | 670.23M | 632.86M |
| Average Diluted Shares Outstanding | 748.83M | 693.93M | 677.00M | 670.23M | 632.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |